Aso Shotaro, Matsui Hiroki, Fushimi Kiyohide, Yasunaga Hideo
Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Crit Care. 2016 Apr 5;20:80. doi: 10.1186/s13054-016-1261-1.
The mortality rate of severely ill patients treated with venoarterial extracorporeal membrane oxygenation (VA-ECMO) remains unknown because of differences in patient background, clinical settings, and sample sizes between studies. We determined the in-hospital mortality of VA-ECMO patients and the proportion weaned from VA-ECMO using a national inpatient database in Japan.
Patients aged ≥ 19 years who received VA-ECMO during hospitalization for cardiogenic shock, pulmonary embolism, hypothermia, poisoning, or trauma between 1 July 2010 and 31 March 2013 were identified, using The Japanese Diagnosis Procedure Combination national inpatient database.
The primary outcome was in-hospital mortality and the secondary outcome was the proportion weaned from VA-ECMO. A total of 5263 patients received VA-ECMO during the study period. The majority of patients had cardiogenic shock (n = 4,658). The number of patients weaned from VA-ECMO was 3389 (64.4%) and in-hospital mortality after weaning from VA-ECMO was 1994 (37.9%). In-hospital mortality without cardiac arrest in the cardiogenic shock group was significantly lower than that in patients with cardiac arrest (70.5% vs. 77.1%, p <0.001). In the multivariable logistic regression including multiple imputation, higher age and greater or smaller body mass index were significantly associated with in-hospital mortality, whereas hospital volume was not associated with such mortality.
The present nationwide study showed high mortality rates in patients who received VA-ECMO, and in particular in patients with cardiogenic shock and in patients with cardiac arrest. Weaning from VA-ECMO did not necessarily result in survival. Further studies are warranted to clarify risk-adjusted mortality of VA-ECMO using more detailed data on patient background.
由于研究之间患者背景、临床环境和样本量存在差异,静脉-动脉体外膜肺氧合(VA-ECMO)治疗的重症患者死亡率尚不清楚。我们使用日本全国住院患者数据库确定了VA-ECMO患者的院内死亡率以及脱机VA-ECMO的比例。
利用日本诊断程序组合全国住院患者数据库,识别出2010年7月1日至2013年3月31日期间因心源性休克、肺栓塞、体温过低、中毒或创伤住院期间接受VA-ECMO治疗的≥19岁患者。
主要结局为院内死亡率,次要结局为脱机VA-ECMO的比例。在研究期间,共有5263例患者接受了VA-ECMO治疗。大多数患者患有心源性休克(n = 4658)。脱机VA-ECMO的患者有3389例(64.4%),脱机VA-ECMO后的院内死亡率为1994例(37.9%)。心源性休克组无心脏骤停患者的院内死亡率显著低于有心脏骤停的患者(70.5%对77.1%,p<0.001)。在包括多重填补法的多变量逻辑回归分析中,年龄较大以及体重指数较高或较低与院内死亡率显著相关,而医院规模与这种死亡率无关。
目前这项全国性研究表明,接受VA-ECMO治疗的患者死亡率很高,尤其是心源性休克患者和心脏骤停患者。脱机VA-ECMO不一定能存活。有必要开展进一步研究,利用更详细的患者背景数据来阐明VA-ECMO的风险调整死亡率。